<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="style.css">
    <title>Antigenic Characterisation of Alphaviruses - Research Poster</title>
</head>

<body>
    <!-- Navigation Bar -->
    <nav class="navbar">
        <div class="nav-left">
            <span class="logo">SCIE3121</span>
        </div>
        <button class="menu-toggle" id="menuToggle">
            <span></span>
            <span></span>
            <span></span>
        </button>
        <ul class="nav-links" id="navLinks">
            <li><a href="#home" class="nav-item">Home</a></li>
            <li><a href="#background-section" class="nav-item">Background</a></li>
            <li><a href="#methods-section" class="nav-item">Methods</a></li>
            <li><a href="#results-section" class="nav-item">Results & Key Findings</a></li>
            <li><a href="#future-section" class="nav-item">Future Directions</a></li>
        </ul>
    </nav>

    <!-- Hero Section - Poster Title -->
    <section class="hero_section" id="home">
        <div class="section_container">
            <div class="hero_container">
                <div class="text_section">
                    <h1>Antigenic Characterisation of Pathogenic and Chimeric Alphaviruses Using a Novel Insect-Specific Platform</h1>
                    <p class="subtitle">Research Project | SCIE3121</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Main Poster Content -->
    <section class="poster_content" id="poster">
        <div class="section_container">
            <!-- Research Highlights Grid -->
            <div class="poster_grid">
                <!-- Background -->
                    <div class="poster_card">
                        <h3>Background</h3>
                        <p>Alphaviruses such as Chikungunya cause widespread outbreaks and are under‑detected due to misdiagnosis and limited laboratory access; an insect‑specific platform enables safe antigenic study in this context.</p>
                    </div>

                    <!-- Aims -->
                    <div class="poster_card">
                        <h3>Aims</h3>
                        <p>
                            1.	Evaluate the potential of 11F4 as a pan-alphavirus antibody. <br>
                            2.	Antigenic Characterization of Chimeric Alphaviruses.
                        </p>
                    </div>

                    <!-- Methods -->
                    <div class="poster_card">
                        <h3>Methods</h3>
                        <p>Chimeric constructs were generated by CPER and expressed in insect cells. Antigen expression and antibody binding were assessed by ELISA, SDS‑PAGE and TCID50 assays.</p>
                    </div>

                    <!-- Key Findings -->
                    <div class="poster_card">
                        <h3>Key Findings</h3>
                        <p>Results show ...</p>
                    </div>
                    </div>
            </div>
        </div>
    </section>

    <!-- Background Section -->
    <section class="detail_section" id="background-section">
        <div class="section_container">
            <div class="detail_content">
                <h2>Background</h2>

                <div class="content_section">
                    <h3>Alphaviruses</h3>
                    <p>Alphaviruses, including Chikungunya virus (CHIKV), Ross River virus (RRV), and equine encephalitis viruses, cause large outbreaks across Central and East Africa, Southeast Asia, and South America. CHIKV transmission has been reported in over 100 countries with an estimated 35 million infections annually. Frequent misdiagnosis with pathogens such as dengue or influenza and limited access to confirmatory laboratory testing have constrained surveillance and vaccine development in endemic regions.</p>

                    <p>Alphaviruses are small, enveloped RNA viruses with a positive-sense, single-stranded genome transmitted by blood-feeding vectors (most commonly mosquitoes). They cause acute febrile illness, arthralgia, and, in some cases, encephalitis. Definitive diagnosis often requires laboratory methods such as RT‑PCR, highlighting the need for accessible, affordable rapid diagnostics in low-resource settings.</p>
                </div>

                <div class="content_section">
                    <h3>Insect-Specific Viruses (ISVs)</h3>
                    <p>Advances in next-generation sequencing and metagenomic surveillance have identified diverse insect-specific viruses (ISVs) that do not replicate in vertebrate cells. While early ISV work concentrated on flaviviruses and chimeric vaccines, parallel studies using insect-specific alphaviruses (ISAs) such as Yada Yada Virus (YYV) and Eilat Virus (EILV) are yet to be conducted.</p>
                </div>

                <div class="content_section">
                    <h3>Alphavirus Genome Structure</h3>
                    <p> The alphavirus genome consists of a single 11.4 kb RNA genome encoding 6 structural proteins and 4 nonstructural proteins as shown in Figure 1b. The structural proteins include the envelope proteins (E1-3), transframe (TF), 6K, and capsid protein. The envelope (E) protein displayed on the surface of the virion consists of E1 and E2. These interact, forming dimers which assemble to form E protein. </p>
                    <figure class="figure">
                        <img src="images/Alphavirus_Virion_and_Genome_Structure.png" alt="Alphavirus particle and genome diagram" title="Alphavirus virion and genome structure">
                        <figcaption>A) Illustrates virion structure showing the placements of E and capsid proteins and the viral envelope and genomic RNA within the mature virion. B) Organization of the positive single strand RNA genome highlighting the nonstructural and structural genes. Adapted from Holmes et al. (2020). </figcaption>
                    </figure>
                </div>

                <div class="content_section">
                    <h3>Challenges</h3>
                    <p>Despite their global burden, there are currently no licensed vaccines or targeted antiviral therapies for most alphaviruses, leaving communities at risk for long-lasting disease burden and recurring outbreaks. Over the last decade monoclonal antibodies (mAbs) have been central to the advancement of diagnostics and therapeutics for a range of pathogens, due to their homogeneity, reproducibility, scalability, and ability to recognize unique epitopes. mAbs represent a method to protect high-risk groups, including individuals who do not respond well to vaccination and those who are immunocompromised. </p>
                </div>

                <div class="content_section">
                    <div class="highlight_box">
                        <h4>Project Aims:</h4>
                        <p>1) Evaluate the potential of 11F4 as a pan-alphavirus antibody.<br>2) Antigenic characterisation of chimeric alphaviruses.</p>
                    </div>
                </div>

            </div>
        </div>
    </section>

    <!-- Methods Section -->
    <section class="detail_section" id="methods-section">
        <div class="section_container">
            <div class="detail_content">
                <h2>Methods</h2>

                <div class="content_section">
                    <h3>Molecular Cloning Strategy</h3>
                    <p>Chimeras were generated using circular polymerase extension reaction (CPER).</p>
                    <ul>
                        <li><strong>CPER:</strong> Due to the limitations of traditional cloning methods, bacterium-free methods such as circular polymerase extension reaction (CPER) have been developed. CPER involves amplifying viral cDNA fragments and a linker fragment containing a CMV promoter which are assembled into circular DNA and transfected into cells to recover infectious virus. This is advantageous as it allows for the manipulation of viral genome sequences via standard PCR strategies enabling rapid and reliable generation of recombinant infectious clones.</li>
                    </ul>
                    <figure class="figure">
                        <img src="images/Schematic Overview of CPER Assembly and Workflow.png" alt="CPER assembly workflow diagram" title="Schematic overview of CPER assembly and workflow">
                        <figcaption>CPER schematic: (A) YYV backbone with VIA inserts showing PCR fragment amplification and UTR linker; (B) CPER workflow demonstrating fragment denaturation, annealing of complementary overlaps, extension to form circular dsDNA plasmid, and transfection for viral expression.</figcaption>
                    </figure>
                </div>

                <div class="content_section">
                    <h3>Antigenic Characterisation Methods</h3>
                    
                    <h4 style="margin-top: 1.5rem;">Enzyme-Linked Immunosorbent Assay (ELISA)</h4>
                    <ul>
                        <li> <b> Coating ELISA:</b> ...</li>
                        <li> <b> Kd ELISA:</b> The dissociation constant of antibodies will be used to compare the antigenic properties of chimeric viruses to their wild-type counterparts.</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">SDS-PAGE</h4>
                    <ul>
                        <li>Virus concentration was estimated using BSA standards.</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">TCID50 Assays</h4>
                    <ul>
                        <li>Used to determine the concentration of newly generated virus stocks.</li>
                    </ul>
                </div>

            </div>
        </div>
    </section>

    <!-- Results Section -->
    <section class="detail_section" id="results-section">
        <div class="section_container">
            <div class="detail_content">
                <h2>Results</h2>

                <div class="content_section">
                    <h3>Antigenic Properties</h3>
                    
                    <h4 style="margin-top: 1.5rem;">ELISA Results</h4>
                    <ul>
                        <li><strong>Coating ELISA:</strong> ... </li>
                        <li><strong>Kd ELISA:</strong> ... </li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Summary of Key Findings</h3>
                    <ul>
                        <li>Put key findings here!</li
                    </ul>
                </div>

            </div>
        </div>
    </section>

    <!-- Future Section -->
    <section class="detail_section" id="future-section">
        <div class="section_container">
            <div class="detail_content">
                <h2>Future Directions</h2>

                <div class="content_section">
                    <h3>Dissociation Constant (kd) Analysis</h3>
                    <p>While this project focused on antigenic characterisation, due to time limitations the project only focused on a limited panel of viruses, including: </p>
                    <ul>
                        <li></li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Applications</h3>

                    <h4 style="margin-top: 1.5rem;">Diagnostic Development</h4>
                    <ul>
                        <li>...</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">Antiviral Development</h4>
                    <ul>
                        <li>...</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">Vaccine Development</h4>
                    <ul>
                        <li>...</li>
                    </ul>

                </div>

                <div class="highlight_box">
                    <h4>Conclusion:</h4>
                    <p>This research establishes a critical foundation for understanding chimeric alphavirus antigenicity. The insect-specific platform offers safe studies against dangerous pathogens, with applications to alphavirus diagnostics and potential vaccines or antivirals for other emerging infectious diseases.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Footer -->
    <footer class="footer">
        <div class="footer_container">
            <div class="footer_section footer_brand">
                <h3 class="footer_title">Alphavirus Research Project</h3>
                <p class="footer_subtext">Antigenic Characterisation | SCIE3121</p>
            </div>
            <div class="footer_section">
                <h4>Quick Links</h4>
                <ul class="footer_links">
                    <li><a href="#home">Home</a></li>
                    <li><a href="#background-section">Background</a></li>
                    <li><a href="#methods-section">Methods</a></li>
                    <li><a href="#results-section">Results</a></li>
                    <li><a href="#future-section">Future Directions</a></li>
                </ul>
            </div>
        </div>
        <div class="footer_bottom">
            © 2025 SCIE3121 Research Project. All Rights Reserved.
        </div>
    </footer>

    <script src="script.js"></script>
</body>
</html>